Sermorelin vs NAD compares a growth hormone peptide with a cellular coenzyme. Learn how each works, what research shows, and safety considerations.
Sermorelin and NAD+ are two different compounds that often sit on the same longevity clinic menu, and they work on completely different systems in the body. Sermorelin is a synthetic peptide that signals the pituitary gland to release more growth hormone, while NAD+ is a coenzyme that nearly every cell uses for energy metabolism and DNA repair. Neither is FDA-approved for anti-aging, so the real question is which mechanism matches the goal you actually have.
What Is Sermorelin?
Sermorelin is a 29-amino-acid fragment of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary and prompts the gland to release its own growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1) in the liver and other tissues.
Because it works upstream, sermorelin is often described as a gentler option than injecting growth hormone directly. Many people researching growth hormone peptides also compare cjc-1295 no dac vs sermorelin, since both are GHRH analogs that differ mainly in half-life and dosing rhythm.
- Class: Synthetic peptide hormone (GHRH analog)
- Primary effect: Increased endogenous growth hormone and IGF-1
- Common route: Subcutaneous injection, usually at bedtime
- FDA status: Approved historically only as a diagnostic agent for growth hormone deficiency; not approved for anti-aging or body composition
People also confuse sermorelin with peptides that act on fat metabolism rather than growth hormone. Searches like igf-1 lr3 vs sermorelin and sermorelin vs aod 9604 come from that confusion: IGF-1 LR3 works downstream of growth hormone, while AOD 9604 is a fragment studied for fat loss without growth hormone activity. The same reasoning explains why aod 9604 vs hgh shows up when someone is weighing a fragment against full growth hormone therapy.
What Is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It carries electrons in the reactions that convert food into ATP, and it also serves as a substrate for enzymes such as sirtuins and PARPs that influence DNA repair, inflammation, and stress responses.
NAD+ levels decline with age and with chronic illness, which is the basis for the claim that restoring them supports healthy aging. Delivery matters a great deal here: oral NAD+ is largely broken down in the digestive tract, so most clinics use IV infusions, subcutaneous injections, or precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).
NAD+ has no meaningful effect on growth hormone, IGF-1, or the pituitary. When people search nad and sermorelin together, they are usually weighing two separate protocols that happen to be sold together, not two versions of the same treatment.
Sermorelin vs NAD+: Side-by-Side Comparison
| Feature | Sermorelin | NAD+ |
|---|---|---|
| Compound type | Synthetic peptide hormone (GHRH analog) | Endogenous coenzyme (dinucleotide) |
| Main mechanism | Stimulates pituitary growth hormone release and raises IGF-1 | Supports cellular energy metabolism and sirtuin/PARP activity |
| Typical goal | Growth hormone and IGF-1 support, body composition, sleep and recovery claims | Energy, focus, metabolic and cellular aging claims |
| Common routes | Subcutaneous injection | IV infusion, subcutaneous injection, nasal spray, oral precursors |
| Typical dose | 100-300 mcg at bedtime | 250-1,000 mg per infusion; 300-1,000 mg oral NR or NMN daily |
| Onset of effects | Weeks to months for IGF-1 changes | Minutes to hours for infusions; weeks for oral precursors |
| Evidence base | Solid for growth hormone deficiency testing; thin for wellness use | Strong for raising NAD+ levels; limited for clinical outcomes |
| FDA status | Not approved for anti-aging; compounding has been restricted | Not approved as a drug; NR sold as a supplement, NMN excluded from supplements |
How Each Is Used in Practice
Sermorelin is almost always self-injected subcutaneously at night, timed to the body's natural overnight growth hormone pulse. Compounded vials require a prescription, and doses usually start low and titrate upward based on IGF-1 labs and tolerability.
NAD+ protocols vary far more widely. A clinic might offer a 250 mg starter infusion over one to two hours, or push doses past 1,000 mg for people who tolerate it. Oral precursors are simpler, but they deliver a different molecule to the bloodstream, so an NR capsule is not equivalent to an NAD+ IV drip.
| Option | Typical protocol | Rough monthly cost in the US |
|---|---|---|
| Compounded sermorelin | 100-300 mcg nightly, subcutaneous | $100-$400 |
| NAD+ IV infusion | 250-1,000+ mg per session, weekly to monthly | $800-$4,000 or more |
| Oral NR or NMN | 300-1,000 mg daily | $30-$80 |
Insurance rarely covers any of these for wellness or anti-aging purposes, and pricing swings widely by clinic and city.
What the Research Shows, and What It Does Not
Sermorelin's evidence base is strongest in diagnostics, where it was used to test pituitary function in children with suspected growth hormone deficiency. Small studies in older adults suggest it can raise growth hormone and IGF-1, but no large trial shows that it improves body composition, sleep, or lifespan in healthy adults.
NAD+ research is broader but still early. Trials of NR and NMN consistently show that oral precursors raise blood NAD+ levels and appear safe over several months, yet improvements in physical function, insulin sensitivity, and cognition have been modest or inconsistent. IV NAD+ infusions themselves have very little controlled trial data behind them.
Raising a biomarker such as IGF-1 or NAD+ is not the same as improving health outcomes. That gap is where most of the marketing lives.
Elevated IGF-1 from growth hormone stimulation is a genuine safety consideration rather than a theoretical one, which is why peptides positioned as growth hormone alternatives get so much attention.
Safety, Side Effects, and Legal Status
Sermorelin side effects include injection site irritation, flushing, headache, and dizziness. Long-term growth hormone and IGF-1 elevation can cause joint pain, fluid retention, carpal tunnel symptoms, and insulin resistance, and people with active cancer or a cancer history are usually advised against growth hormone stimulating peptides.
NAD+ infusions commonly cause chest tightness, nausea, cramping, and flushing when the drip runs too fast; slowing the infusion usually resolves them. Oral precursors can cause nausea or insomnia at higher doses. Neither compound is risk-free simply because it occurs naturally in the body.
In the United States, sermorelin is not FDA-approved for anti-aging and its availability as a compounded product has been restricted. The FDA has also taken the position that NMN is excluded from the dietary supplement category, while NR remains widely sold as a supplement.
A licensed healthcare professional should review your history, medications, and labs before you start either compound, especially if you plan to stack them. If your goal is growth hormone signaling, sermorelin is the relevant option; if your goal is cellular energy metabolism, NAD+ is the relevant option. Neither replaces sleep, resistance training, and adequate protein, and neither is a proven anti-aging drug.
Frequently Asked Questions
Is sermorelin the same thing as NAD+?
No. Sermorelin is a synthetic peptide that stimulates growth hormone release from the pituitary gland, while NAD+ is a coenzyme involved in cellular energy metabolism and DNA repair. They act on entirely different pathways and are not interchangeable.
Can you use sermorelin and NAD+ together?
There is no known direct interaction between the two, and some clinics do offer them as a combined protocol. Combining them raises the cost and the number of side effects you need to monitor, so a prescriber should review your history and labs first.
Which is better for anti-aging, sermorelin or NAD+?
Neither is FDA-approved for anti-aging, and neither has large trials proving it slows aging in healthy adults. Sermorelin raises IGF-1, which carries its own long-term risks, while NAD+ precursors reliably raise NAD+ levels but have shown only modest and inconsistent clinical benefits so far.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.